knowledge -WSS

knowledge

author：entertainment 2025-09-29 01:45:58 - browse：1

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Former medical device CEO who sold dummy, plastic parts convicted of fraud

WSS

In his State of the Union, Biden takes clear aim at 'Big Pharma'

How to bring more disabled researchers into academia

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

Just how do doctors, lawmakers, and the public define abortion?

Long Covid research funding gets a major boost from NIH

Readout Newsletter: Amylyx, Aurinia, and IQVIA

hotspot

knowledge

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

UnitedHealth quietly bought dozens of outpatient centers

Wildfire smoke exposes gaps in outdoor worker protections

UnitedHealth quietly bought dozens of outpatient centers

After affirmative action ruling, medical educators look to 'holistic review'

Report cites 'urgent' need to recruit more diverse clinical trial participants

Dobbs anniversary: the lost opportunity of abortion as health care

Juul documents reveal insider tactics on political lobbying

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

focus

Change Healthcare cyberattack prompts Medicare loan program

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Report cites 'urgent' need to recruit more diverse clinical trial participants

Abbott's new heart device gets FDA advisory panel nod

Long Covid research funding gets a major boost from NIH

UnitedHealth quietly bought dozens of outpatient centers

focus

entertainment

focus

hotspot